80岁以上急性髓细胞白血病患者的治疗现状及研究进展

Present status and research progresses in treatment of acute myeloid leukemia patients aged over 80 years

目前,80岁以上急性髓细胞白血病(AML)患者的数量正在逐年增多,该类患者高龄、基础疾病多、对化疗耐受差,因此治疗效果差,生存期较短。对80岁以上AML患者治疗方法较多,包括支持治疗、标准剂量化疗、减低剂量化疗、去甲基化治疗、造血干细胞移植(HSCT)及过继细胞免疫治疗等,并且上述治疗方法均取得一定的治疗效果。但是,对80岁以上AML患者迄今仍缺乏统一、有效的标准化治疗方案,患者预后仍较差。笔者拟就80岁以上老年AML的治疗现状及研究进展进行综述。

The number of acute myeloid leukemia (AML) patients aged over 80 years are increasing year by year. They have poor treatment effects and shorter survival period because of elderly age, more underlying diseases, poor tolerance to chemotherapy. At present, there are many treatments reported, including supportive therapy, standard-dose chemotherapy, reduced-dose chemotherapy, demethylation therapy, hematopoietic stem cell transplantation(HSCT) and adoptive cellular immunotherapy, and various treatments have achieved some good effects in AML patients aged over 80 years. However, the survival of this group of patients is still poor. And there are lack of unified and effective therapeutic strategies for elderly patients with AML. This article reviewed the present status and research progresses on treatment of AML aged over 80 years.